查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2000582

臍帶血處理產品市場：2026-2032年全球市場預測（依產品類型、處理方法、服務供應商、檢體類型、應用程式和最終用戶分類）

Umbilical Cord Blood Processing Products Market by Product Type, Processing Method, Service Provider, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，臍帶血處理產品市場價值將達到 18.7 億美元，到 2026 年將成長至 20.6 億美元，到 2032 年將達到 39.8 億美元，複合年成長率為 11.42%。

主要市場統計數據
基準年 2025 18.7億美元
預計年份：2026年 20.6億美元
預測年份：2032年 39.8億美元
複合年成長率 (%) 11.42%

本文概述了臍帶血處理產品在臨床創新、品質要求和不斷變化的營運重點方面的策略背景。

本導言重點介紹快速發展的臍帶血處理產品領域，該領域融合了臨床創新、監管進步和營運現代化。細胞療法和再生醫學的進步日益凸顯了精準、高效和無菌處理方案的重要性，促使臨床、研究和商業領域的相關人員重新思考從採集到儲存的整個工作流程。同時，該行業面臨對品管、可追溯性和可擴展性的更高要求，促使各機構重新評估傳統的手工操作方法，轉而採用能夠提高可重複性並降低污染風險的技術。

技術自動化、通訊協定柔軟性和治療方法的進步如何推動混合策略並重塑臨床和研究環境中的處理工作流程？

技術、工作流程設計和政策的變革性轉變正在重新定義人們對臍帶血處理解決方案的期望。自動化不再是小眾的增強功能，而是直接影響可重複性、人力利用率和污染控制的策略工具。旨在最大限度減少操作人員干預並維持無菌屏障的封閉式自動化系統，正成為尋求更高處理能力和更穩定結果的臨床檢查室越來越青睞的選擇。相較之下，開放式系統保持了對專有通訊協定和流程的柔軟性調整，並在方法客製化至關重要的實驗室和小規模臨床機構中繼續發揮重要作用。

為確保品質和供應，我們將審查我們的供應商策略、在地化工作和庫存管理，以克服關稅帶來的採購壓力。

美國關稅的實施增加了臍帶血加工產品相關企業的籌資策略、供應鏈配置和成本管理的複雜性。關稅措施對進口零件和試劑組，關稅帶來的成本壓力可能會加速其尋找替代供應商和改進設計以減輕關稅負擔的進程。

對產品架構、治療應用、最終使用者畫像、加工技術、服務模式和檢體所有權框架進行全面的細分映射。

透過詳細的細分觀點，我們揭示了每種產品類型、應用程式、最終用戶、處理方法、服務供應商和檢體所有權模式的不同需求促進因素和採購行為。基於產品類型，分析區分了“自動化系統”和“手動試劑盒”，其中自動化系統進一步細分為“封閉式系統”和“開放系統”，而手動試劑盒則分為“客製化通訊協定”和“預包裝試劑盒”。這些區分揭示了處理能力、無菌保證和通訊協定柔軟性的權衡。基於應用，我們檢視了免疫療法、再生醫學和移植領域的現況。免疫療法包括CAR-T療法和NK細胞增殖，再生醫學涵蓋組織工程和傷口護理，移植包括造血幹細胞和間質幹細胞的應用。這種應用層面的分析闡明了處理精確度和細胞完整性最為關鍵的領域。

在全球主要市場中，區域管理體制、臨床重點和銀行模式如何影響採購選擇和供應商策略？

區域趨勢對採購偏好、法規要求和合作生態系統有顯著影響。在美洲，先進治療方法研發的集中、活躍的臨床試驗網路以及成熟的私人銀行體系，推動了自動化封閉式系統的早期應用，以支持受監管的臨床工作流程和大規模處理需求。與這些區域特徵形成鮮明對比的是，歐洲、中東和非洲的市場呈現異質性。有些國家擁有統一的監管法規和完善的公共銀行基礎設施，而有些國家則正經歷對私人銀行業務的快速成長。這種環境需要能夠適應不同合規結構和資源限制的模組化解決方案。同時，在亞太地區，大規模的臨床人口、不斷成長的生物技術投資以及政府主導的再生醫學研究支援舉措，共同催生了對高通量自動化平台和適用於分散式設施的便捷手動試劑盒的需求。

透過整合系統耗材設計、服務擴展、供應彈性和策略驗證夥伴關係關係，實現企業級差異化。

企業層面的關鍵趨勢集中在系統設計創新、耗材價格競爭、服務廣度以及連結臨床和研究需求的策略夥伴關係。主要企業透過整合硬體平台、一次性耗材和經過驗證的工作流程的整合解決方案脫穎而出，降低了採用門檻並確保結果可重複。系統製造商與合約測試實驗室和學術機構之間的策略合作加速了在各種應用情境下的驗證，並記錄了第三方在真實環境中的表現證據。同時，將合約處理、方法驗證和培訓服務納入其服務組合的企業正在與優先考慮承包解決方案的最終用戶建立牢固的關係。

為高階主管提供可操作的策略步驟，以平衡自動化規模、供應彈性、驗證透明度和服務主導的部署管道。

產業領導者應務實地將策略投資與戰術性調整結合，以在複雜多變的環境中創造價值。首先，應優先考慮可分階段部署的模組化自動化。企業可以逐步部署用於大批量工作流程的封閉式系統模組，同時保持開放系統功能，用於原型製作和法律開發。這種方法既能控制資本密集度，又能保持柔軟性。其次，應制定雙重採購和區域供應商認證計劃，以降低關稅風險和供應鏈脆弱性，並結合緊急庫存政策，平衡營運資金和關鍵耗材的供應。

為確保研究結果的可靠性，調查方法結合了多方相關人員的初步調查、技術檢驗和同行檢驗的分析程序。

本調查方法結合了多方面的證據基礎和嚴格的檢驗程序，以確保分析的一致性和實用性。主要研究包括與供應商、醫院檢查室、其他實驗室和合約服務供應商等相關人員進行結構化諮詢，以收集有關採購因素、技術選擇標準和營運挑戰的經驗見解。這些定性資訊與技術規範、監管文件和檢驗報告進行交叉比對，以評估產品功能、工作流程相容性和品質系統。同時，次要研究整合了公開文獻、專利和臨床實驗室註冊信息，以了解應用趨勢和技術進步。

策略整合強調柔軟性、驗證性、供應彈性和協作，以此作為永續推廣和臨床影響的基礎。

總之，臍帶血處理產品領域正處於轉折點，自動化、治療方法創新和供應鏈重組在此交匯融合。那些採用靈活策略的企業，能夠將封閉式自動化系統的可重複性和污染控制優勢與手動試劑盒的適應性和成本優勢相結合，從而更有利於滿足臨床和科研環境中多樣化的用戶需求。為了因應區域因素和關稅趨勢帶來的波動，需要進行細緻的價值鏈規劃並建立植根於本地的夥伴關係模式，以維持業務連續性並管控整體成本風險。此外，投資於高度透明的驗證、一體化服務交付以及針對特定應用（例如免疫療法和移植）量身定做的產品藍圖的企業，將能夠為其客戶創造永續的價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 臍帶血處理產品市場：依產品類型分類

  • 自動化系統
    • 封閉式系統
    • 開放系統
  • 手冊套件
    • 客製化通訊協定
    • 預包裝套件

第9章 臍帶血加工產品市場：依加工方法分類

  • 細胞分離
    • CD34 精選
    • 紅血球清除
  • 產能下降
    • 離心分離
    • 過濾

第10章 臍帶血處理產品市場：依服務供應商分類

  • 合約服務
    • 合約研究機構
    • 外部測試機構
  • 內部處理

第11章 臍帶血處理產品市場：依檢體類型分類

  • 私人銀行
    • 自我保護銀行
    • 家庭銀行
  • 大眾銀行

第12章 臍帶血處理產品市場：依應用領域分類

  • 免疫療法
    • CAR-T療法
    • NK細胞增殖
  • 再生醫學
    • 組織工程
    • 傷口護理
  • 移植
    • 造血幹細胞
    • 間質幹細胞

第13章 臍帶血處理產品市場：依最終用戶分類

  • 生技公司
    • 大型製藥企業
    • 小型企業
  • 醫院和診所
    • 大學醫院
    • 當地醫院
  • 研究機構
    • 受託研究機構
    • 大學

第14章 臍帶血處理產品市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 臍帶血處理產品市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 臍帶血加工產品市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國臍帶血處理產品市場

第18章：中國臍帶血加工產品市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Americord Registry LLC
  • China Cord Blood Corporation
  • Cord Blood America, Inc.
  • Cord Blood Registry, LLC
  • Cordlife Group Limited
  • Cryo-Cell International, Inc.
  • CryoHoldco, SAPI de CV
  • LifeCell International Pvt. Ltd.
  • Maze Cord Blood Laboratories, Inc.
  • New England Cryogenic Center, Inc.
  • ReeLabs Pvt. Ltd.
  • StemCyte, Inc.
  • ViaCord, LLC
  • Vita 34 AG
Product Code: MRR-6849E8ED80B7

The Umbilical Cord Blood Processing Products Market was valued at USD 1.87 billion in 2025 and is projected to grow to USD 2.06 billion in 2026, with a CAGR of 11.42%, reaching USD 3.98 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.87 billion
Estimated Year [2026] USD 2.06 billion
Forecast Year [2032] USD 3.98 billion
CAGR (%) 11.42%

Framing the strategic context for umbilical cord blood processing products amid clinical innovation, quality demands, and evolving operational priorities

The introduction establishes the context for a rapidly evolving domain where umbilical cord blood processing products intersect clinical innovation, regulatory evolution, and operational modernization. Advances in cell-based therapies and regenerative medicine have elevated the importance of precise, efficient, and sterility-assured processing solutions, prompting stakeholders across clinical, research, and commercial settings to reassess workflows from collection to storage. Simultaneously, the industry faces intensified scrutiny around quality controls, traceability, and scalability, leading organizations to reconsider traditional manual approaches in favor of technologies that promise reproducibility and reduced contamination risk.

Against this backdrop, the report frames key thematic drivers shaping strategic choices: integration of automated systems within existing laboratory infrastructures; differentiation between closed and open-system architectures; and the trade-offs between customizable manual kit protocols and prepackaged kits that prioritize speed and compliance. It also establishes a lens for evaluating end-user needs spanning biotechnology companies, hospitals and clinics, and research institutions, each with distinct priorities linked to therapeutic pipelines, clinical throughput, and investigational activity. This foundational overview prepares executives to interpret subsequent analysis through a pragmatic lens that emphasizes operational readiness, regulatory alignment, and the potential for cross-sector collaboration.

How technological automation, protocol flexibility, and therapeutic advances are driving hybrid strategies and reshaping processing workflows across clinical and research settings

Transformative shifts across technology, workflow design, and policy are redefining expectations for cord blood processing solutions. Automation is no longer a niche enhancement but a strategic lever that directly affects reproducibility, labor utilization, and contamination control. Closed automated systems, designed to minimize operator intervention and maintain aseptic barriers, are increasingly attractive to clinical laboratories pursuing higher throughput and consistent outcomes. By contrast, open systems retain flexibility for bespoke protocols and process adjustments, keeping them relevant for research settings and small-scale clinical operations where method customization is essential.

Manual kits continue to play a complementary role, particularly where protocols demand adaptability or where capital expenditure constraints delay automation adoption. Customizable manual protocols enable process tailoring for niche applications, while prepackaged kits deliver simplified workflows that aid compliance and operator training. Concurrently, application-level shifts such as the maturation of CAR-T therapies and expanding regenerative medicine techniques emphasize the need for processing methods that preserve cell viability and functional characteristics. These converging shifts compel organizations to adopt hybrid strategies that balance the rigor and scalability of automated systems with the adaptability and lower initial costs of manual kits, thereby positioning them to respond to both clinical and investigational demands.

Navigating tariff-driven procurement pressures by recalibrating supplier strategies, localization efforts, and inventory practices to protect quality and availability

The imposition of tariffs in the United States introduces a complex overlay to procurement strategies, supply chain configurations, and cost management for firms involved in cord blood processing products. Tariff measures affect imported components and complete systems differently, altering vendor selection calculus and encouraging buyers to reassess supplier diversification, nearshoring options, and inventory policies. For manufacturers that rely on global supply chains for specialized components such as sterile single-use assemblies, centrifuge rotors, or reagent kits, tariff-related cost pressures may accelerate efforts to qualify alternative suppliers or to reconfigure designs to reduce tariff exposure.

In response, some organizations are likely to adopt strategic stockpiling of critical consumables or to renegotiate long-term contracts to stabilize unit costs. Others may pursue localization strategies, including partnerships with domestic contract manufacturers or investments in regional assembly capabilities that mitigate tariff risk while preserving access to technological expertise. The tariff environment also affects pricing negotiations with end users, particularly for hospitals and research institutions operating under constrained budgets. Ultimately, tariffs act as a catalyst for operational resilience planning, driving a closer alignment between procurement, regulatory compliance, and product development teams to manage total cost of ownership while maintaining quality and availability of processing supplies and systems.

Comprehensive segmentation mapping across product architectures, therapeutic uses, end-user profiles, processing techniques, service models, and sample ownership frameworks

A nuanced segmentation view reveals differentiated demand drivers and procurement behaviors across product types, applications, end users, processing methods, service providers, and sample ownership models. Based on product type, analysis distinguishes between Automated Systems and Manual Kits, with Automated Systems further categorized into Closed Systems and Open Systems, and Manual Kits differentiated into Customizable Protocols and Prepackaged Kits; these distinctions illuminate trade-offs between throughput, sterility assurance, and protocol flexibility. Based on application, the landscape is examined across Immunotherapy, Regenerative Medicine, and Transplantation, where Immunotherapy includes CAR-T Therapy and NK Cell Expansion, Regenerative Medicine covers Tissue Engineering and Wound Healing, and Transplantation encompasses Hematopoietic Stem Cell and Mesenchymal Stem Cell uses; this application-level breakdown clarifies where processing fidelity and cell integrity are most mission-critical.

Based on end user, the market comprises Biotechnology Companies, Hospitals And Clinics, and Research Institutions, with Biotechnology Companies subdivided into Large Pharma and SMEs, Hospitals And Clinics split into Academic Hospitals and Community Hospitals, and Research Institutions incorporating Contract Research Organizations and Universities; these end-user definitions help explain procurement cycles, regulatory expectations, and adoption velocity. Based on processing method, analysis identifies Cell Separation and Volume Reduction, with Cell Separation including CD34 Selection and Red Cell Depletion, and Volume Reduction differentiating Centrifugation and Filtration; understanding these methodological choices is essential for evaluating equipment and consumable compatibility. Based on service provider, distinctions between Contract Services and In-House operations highlight the roles of Contract Research Organizations and Third-Party Laboratories in scaling specialized processing, while based on sample type, the market differentiates Private Banks and Public Banks, with Private Banks further classified into Autologous Banks and Family Banks; this ownership segmentation affects quality standards, custodial responsibilities, and commercial models. Together, these intersecting dimensions provide a comprehensive lens to align product design, regulatory compliance, and go-to-market approaches with distinct customer needs.

How regional regulatory regimes, clinical priorities, and banking models shape procurement choices and vendor strategies across major global markets

Regional dynamics exert a powerful influence on procurement preferences, regulatory requirements, and collaborative ecosystems. In the Americas, a concentration of advanced therapeutic development, active clinical trial networks, and a mature private banking sector favors early adoption of automated and closed systems that support regulated clinical workflows and large-scale processing demands. Transitioning from this regional profile, Europe, Middle East & Africa presents a heterogeneous mix of markets where regulatory harmonization and public bank infrastructures in some countries coexist with rapidly growing private banking interest in others; this environment encourages modular solutions that can be adapted to varied compliance regimes and resource constraints. Meanwhile, Asia-Pacific exhibits a blend of high-volume clinical populations, expanding biotech investment, and governmental initiatives that support regenerative medicine research, all of which create demand for both high-throughput automated platforms and accessible manual kits suited to decentralized facilities.

Across regions, differences in reimbursement frameworks, clinical trial regulatory pathways, and the prevalence of public versus private cord blood banks shape procurement and deployment timelines. For instance, regions with robust public bank networks may prioritize processing methods that optimize cell yield for transplantation, while markets with accelerating immunotherapy pipelines prioritize technologies that preserve functional cell characteristics relevant to ex vivo expansion. These regional nuances encourage vendors and service providers to pursue differentiated market entry strategies, collaborate with local laboratories and academic centers for validation studies, and design service offerings that reflect regional expectations for quality assurance, traceability, and customer support.

Company-level differentiation driven by integrated system-consumable design, service expansion, supply resilience, and strategic validation partnerships

Key company-level dynamics center on innovation in system design, consumable affordability, service breadth, and strategic partnerships that bridge clinical and research needs. Leading organizations differentiate themselves through integrated offerings that combine hardware platforms, single-use consumables, and validated workflows to reduce adoption friction and ensure reproducible outcomes. Strategic collaborations between system manufacturers and contract laboratories or academic centers accelerate validation across varied use cases and provide third-party evidence of performance under real-world conditions. Meanwhile, companies that expand service portfolios to include contract processing, method validation, and training services create sticky relationships with end users who prioritize turnkey solutions.

Operational excellence in manufacturing, supply chain resilience, and regulatory support are decisive competitive levers. Firms that invest in scalable production capacity for sterile disposables and that maintain multiple qualified suppliers for critical components mitigate disruption risks and protect customer continuity. At the same time, commercial strategies that address differentiated buyer segments-such as offering compact, cost-efficient kits for community hospitals and modular automated platforms for large research centers-enhance market reach. Finally, intellectual property around cell selection technologies, closed-system interfaces, and assay-compatible consumables can provide defensible differentiation, while transparent quality management and third-party certifications reinforce trust among clinical and research customers.

Actionable strategic steps for executives to balance automation scale, supply resilience, validation transparency, and service-led adoption pathways

Industry leaders should adopt a pragmatic mix of strategic investments and tactical adjustments to capture value in a complex, evolving landscape. First, prioritize modular automation that allows incremental deployment: organizations can phase in closed-system modules for high-volume workflows while retaining open-system capabilities for prototyping and method development. This approach preserves flexibility and manages capital intensity. Second, develop dual sourcing and regional supplier qualification programs to reduce tariff exposure and supply chain vulnerability, and couple those programs with contingency inventory policies that balance working capital with availability of critical consumables.

Third, invest in rigorous validation studies and publish technical performance data to shorten procurement cycles and build trust among hospital procurement teams and research institutions. Fourth, expand service portfolios to include method transfer support, training, and contract processing options that lower adoption barriers and create recurring revenue streams. Fifth, align product roadmaps with application-specific requirements-such as protocols optimized for CAR-T manufacturing or for mesenchymal stem cell preservation-ensuring that design choices reflect the sensitivity of target cell populations. Finally, cultivate strategic partnerships with banks, academic centers, and biotechnology companies to co-develop workflows and to secure early adopters for new platform releases, thereby accelerating field validation and commercial traction.

Methodological framework combining multi-stakeholder primary research, technical validation, and cross-checked analytical procedures to ensure robust insights

The research methodology combines a multi-source evidence base with rigorous validation steps to ensure analytical integrity and operational relevance. Primary research included structured consultations with stakeholders across vendors, hospital laboratories, research institutions, and contract service providers to capture experiential insights into procurement drivers, technology selection criteria, and operational pain points. These qualitative inputs were triangulated with technical specifications, regulatory documentation, and validation reports to assess product capabilities, workflow compatibility, and quality systems. In parallel, secondary research synthesized publicly available literature, patents, and clinical trial registries to map application trends and technological trajectories.

Analytical procedures emphasized cross-validation and scenario analysis. For example, technology capability assessments were reviewed against third-party validation studies and user-reported performance data to reconcile controlled-lab claims with real-world performance. Segmentation constructs were stress-tested through interviews with representative end users to ensure that categories-spanning product type, application, end user, processing method, service provider, and sample type-reflect practical decision-making frames. Finally, sensitivity checks and expert review panels were used to surface divergent viewpoints and to refine interpretations, ensuring that conclusions are grounded in a balanced appraisal of technological potential, operational constraints, and regulatory context.

Strategic synthesis emphasizing flexibility, validation, supply resilience, and collaboration as the foundation for sustained adoption and clinical impact

In conclusion, the domain of umbilical cord blood processing products is at an inflection point defined by the interplay of automation, therapeutic innovation, and supply chain realignment. Organizations that adopt flexible strategies-combining the reproducibility and contamination control benefits of closed automated systems with the adaptability and cost advantages of manual kits-will be better positioned to meet diverse user needs across clinical and research settings. Regional and tariff-driven dynamics require deliberate supply chain planning and localized partnership models to maintain continuity and control total cost exposure. Moreover, companies that invest in transparent validation, integrated service offerings, and targeted product roadmaps aligned with specific applications such as immunotherapy and transplantation will create durable value for customers.

Looking forward, the most resilient players will be those that incorporate iterative learning into product development, maintain diversified sourcing, and actively collaborate with clinical and academic partners to validate performance in situ. By emphasizing operational readiness, regulatory alignment, and customer-centric services, stakeholders can convert technical capabilities into sustained adoption and improved patient and research outcomes. This concluding synthesis underscores the importance of strategic adaptability as the cornerstone of long-term success in a rapidly evolving field.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Umbilical Cord Blood Processing Products Market, by Product Type

  • 8.1. Automated Systems
    • 8.1.1. Closed Systems
    • 8.1.2. Open Systems
  • 8.2. Manual Kits
    • 8.2.1. Customizable Protocols
    • 8.2.2. Prepackaged Kits

9. Umbilical Cord Blood Processing Products Market, by Processing Method

  • 9.1. Cell Separation
    • 9.1.1. CD34 Selection
    • 9.1.2. Red Cell Depletion
  • 9.2. Volume Reduction
    • 9.2.1. Centrifugation
    • 9.2.2. Filtration

10. Umbilical Cord Blood Processing Products Market, by Service Provider

  • 10.1. Contract Services
    • 10.1.1. Contract Research Organizations
    • 10.1.2. Third-Party Laboratories
  • 10.2. In-House

11. Umbilical Cord Blood Processing Products Market, by Sample Type

  • 11.1. Private Banks
    • 11.1.1. Autologous Banks
    • 11.1.2. Family Banks
  • 11.2. Public Banks

12. Umbilical Cord Blood Processing Products Market, by Application

  • 12.1. Immunotherapy
    • 12.1.1. CAR-T Therapy
    • 12.1.2. NK Cell Expansion
  • 12.2. Regenerative Medicine
    • 12.2.1. Tissue Engineering
    • 12.2.2. Wound Healing
  • 12.3. Transplantation
    • 12.3.1. Hematopoietic Stem Cell
    • 12.3.2. Mesenchymal Stem Cell

13. Umbilical Cord Blood Processing Products Market, by End User

  • 13.1. Biotechnology Companies
    • 13.1.1. Large Pharma
    • 13.1.2. SMEs
  • 13.2. Hospitals And Clinics
    • 13.2.1. Academic Hospitals
    • 13.2.2. Community Hospitals
  • 13.3. Research Institutions
    • 13.3.1. Contract Research Organizations
    • 13.3.2. Universities

14. Umbilical Cord Blood Processing Products Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Umbilical Cord Blood Processing Products Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Umbilical Cord Blood Processing Products Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Umbilical Cord Blood Processing Products Market

18. China Umbilical Cord Blood Processing Products Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Americord Registry LLC
  • 19.6. China Cord Blood Corporation
  • 19.7. Cord Blood America, Inc.
  • 19.8. Cord Blood Registry, LLC
  • 19.9. Cordlife Group Limited
  • 19.10. Cryo-Cell International, Inc.
  • 19.11. CryoHoldco, S.A.P.I. de C.V.
  • 19.12. LifeCell International Pvt. Ltd.
  • 19.13. Maze Cord Blood Laboratories, Inc.
  • 19.14. New England Cryogenic Center, Inc.
  • 19.15. ReeLabs Pvt. Ltd.
  • 19.16. StemCyte, Inc.
  • 19.17. ViaCord, LLC
  • 19.18. Vita 34 AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PROCESSING METHOD, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SERVICE PROVIDER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CLOSED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CLOSED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CLOSED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY OPEN SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY OPEN SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY OPEN SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CUSTOMIZABLE PROTOCOLS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CUSTOMIZABLE PROTOCOLS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CUSTOMIZABLE PROTOCOLS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PREPACKAGED KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PREPACKAGED KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PREPACKAGED KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PROCESSING METHOD, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CD34 SELECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CD34 SELECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CD34 SELECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RED CELL DEPLETION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RED CELL DEPLETION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RED CELL DEPLETION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CENTRIFUGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CENTRIFUGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CENTRIFUGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FILTRATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FILTRATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FILTRATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY THIRD-PARTY LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY THIRD-PARTY LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY THIRD-PARTY LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IN-HOUSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IN-HOUSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IN-HOUSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOLOGOUS BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOLOGOUS BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOLOGOUS BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FAMILY BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FAMILY BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY FAMILY BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PUBLIC BANKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PUBLIC BANKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PUBLIC BANKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CAR-T THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CAR-T THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CAR-T THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY NK CELL EXPANSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY NK CELL EXPANSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY NK CELL EXPANSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TISSUE ENGINEERING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TISSUE ENGINEERING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TISSUE ENGINEERING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY WOUND HEALING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY WOUND HEALING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY WOUND HEALING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SMES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SMES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SMES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY ACADEMIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY ACADEMIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY ACADEMIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COMMUNITY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PROCESSING METHOD, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PROCESSING METHOD, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PROCESSING METHOD, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PROCESSING METHOD, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PROCESSING METHOD, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPE UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPE UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PROCESSING METHOD, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. MIDDLE EAST UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2032 (USD MILLION)
  • TABLE 248. MIDDLE EAST UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY MANUAL KITS, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PROCESSING METHOD, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CELL SEPARATION, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY VOLUME REDUCTION, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY CONTRACT SERVICES, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY PRIVATE BANKS, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2032 (USD MILLION)
  • TABLE 262. AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 263. AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY TRANSPLANTATION, 2018-2032 (USD MILLION)
  • TABLE 264. AFRICA UMBILICAL CORD BLOOD PROCESSING PRODUCTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. AFRICA UMBILICAL CORD BLOOD PROCE